---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-008228"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:16:02.112328+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma completes IPO of 9.7M shares at $18, raising ~$175M

## Summary
- IPO of 9,722,222 shares of common stock at $18.00 per share closed January 30, 2024.
- Gross proceeds to the company were approximately $175.0 million before expenses.
- Amended and restated certificate of incorporation and bylaws filed and effective upon IPO closing.
- Common stock trades on Nasdaq under ticker AVBP.

## SEC filing metadata
- accession: 0001104659-24-008228
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/0001104659-24-008228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/tm2321853d25_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-008228
- JSON: https://secwatch.observer/filing/0001104659-24-008228.json
- Plain text: https://secwatch.observer/filing/0001104659-24-008228.txt

## Key facts
- Governance Changes
  ArriVent BioPharma, Inc.: Amended and restated certificate of incorporation filed in connection with closing of IPO (effective 2024-01-30).
  - Change: charter amendment
  - Effective: 2024-01-30
  source text: On January 30, 2024, ArriVent BioPharma, Inc. (the “Company”) filed its amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of its initial public offering (the “IPO”) of common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/0001104659-24-008228-index.htm
- Governance Changes
  ArriVent BioPharma, Inc.: Adopted amended and restated bylaws in connection with closing of IPO (effective 2024-01-30).
  - Change: bylaw amendment
  - Effective: 2024-01-30
  source text: The Company also adopted its amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465924008228/0001104659-24-008228-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.